|
1. Stratton MR, Campbell PJ, Futreal PA: The cancer genome. Nature 2009, 458(7239):719-724.
2. Neal CL, Yu D: 14-3-3zeta as a prognostic marker and therapeutic target for cancer. Expert opinion on therapeutic targets 2010, 14(12):1343-1354.
3. Cowling VH, Cole MD: Mechanism of transcriptional activation by the Myc oncoproteins. Seminars in cancer biology 2006, 16(4):242-252.
4. Pacal M, Bremner R: Insights from animal models on the origins and progression of retinoblastoma. Current molecular medicine 2006, 6(7):759-781.
5. Contessa JN, Hampton J, Lammering G, Mikkelsen RB, Dent P, Valerie K, Schmidt-Ullrich RK: Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene 2002, 21(25):4032-4041.
6. Codegoni AM, Nicoletti MI, Buraggi G, Valoti G, Giavazzi R, D'Incalci M, Landoni F, Maneo A, Broggini M: Molecular characterisation of a panel of human ovarian carcinoma xenografts. European journal of cancer 1998, 34(9):1432-1438.
7. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA et al: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286(5439):531-537.
8. Thomas JG, Olson JM, Tapscott SJ, Zhao LP: An efficient and robust statistical modeling approach to discover differentially expressed genes using genomic expression profiles. Genome research 2001, 11(7):1227-1236.
9. Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD: Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer research 2002, 62(10):2890-2896.
10. Liu KQ, Liu ZP, Hao JK, Chen L, Zhao XM: Identifying dysregulated pathways in cancers from pathway interaction networks. BMC bioinformatics 2012, 13:126.
11. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Nozoe T, Yasumoto K: Expression of the p53 family in lung cancer. Anticancer research 2006, 26(3A):1785-1790.
12. Braga-Neto UM, Dougherty ER: Is cross-validation valid for small-sample microarray classification? Bioinformatics 2004, 20(3):374-380.
13. Peltonen L, McKusick VA: Genomics and medicine. Dissecting human disease in the postgenomic era. Science 2001, 291(5507):1224-1229.
14. Glazier AM, Nadeau JH, Aitman TJ: Finding genes that underlie complex traits. Science 2002, 298(5602):2345-2349.
15. Merikangas KR, Low NC, Hardy J: Commentary: understanding sources of complexity in chronic diseases--the importance of integration of genetics and epidemiology. International journal of epidemiology 2006, 35(3):590-592; discussion 593-596.
16. Rybaczyk LA, Bashaw MJ, Pathak DR, Huang K: An indicator of cancer: downregulation of monoamine oxidase-A in multiple organs and species. BMC genomics 2008, 9:134.
17. Liu X, Liu ZP, Zhao XM, Chen L: Identifying disease genes and module biomarkers by differential interactions. Journal of the American Medical Informatics Association : JAMIA 2012, 19(2):241-248.
18. Kar G, Gursoy A, Keskin O: Human cancer protein-protein interaction network: a structural perspective. PLoS computational biology 2009, 5(12):e1000601.
19. Chu LH, Chen BS: Construction of a cancer-perturbed protein-protein interaction network for discovery of apoptosis drug targets. BMC systems biology 2008, 2:56.
20. Wang YC, Chen BS: A network-based biomarker approach for molecular investigation and diagnosis of lung cancer. BMC medical genomics 2011, 4:2.
21. Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, Kim MJ, Yun SJ, Lee KM, Moon SK et al: Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Molecular cancer 2010, 9:3.
22. Sheffer M, Bacolod MD, Zuk O, Giardina SF, Pincas H, Barany F, Paty PB, Gerald WL, Notterman DA, Domany E: Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(17):7131-7136.
23. Roessler S, Long EL, Budhu A, Chen Y, Zhao X, Ji J, Walker R, Jia HL, Ye QH, Qin LX et al: Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology 2012, 142(4):957-966 e912.
24. Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, Thorgeirsson SS, Sun Z, Tang ZY, Qin LX et al: A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer research 2010, 70(24):10202-10212.
25. Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens JA, Hoogsteden HC et al: Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PloS one 2010, 5(4):e10312.
26. Vogl A, Sartorius U, Vogt T, Roesch A, Landthaler M, Stolz W, Becker B: Gene expression profile changes between melanoma metastases and their daughter cell lines: implication for vaccination protocols. The Journal of investigative dermatology 2005, 124(2):401-404.
27. Medeiros F, Rigl CT, Anderson GG, Becker SH, Halling KC: Tissue handling for genome-wide expression analysis: a review of the issues, evidence, and opportunities. Archives of pathology & laboratory medicine 2007, 131(12):1805-1816.
28. Chatr-Aryamontri A, Breitkreutz BJ, Heinicke S, Boucher L, Winter A, Stark C, Nixon J, Ramage L, Kolas N, O'Donnell L et al: The BioGRID interaction database: 2013 update. Nucleic acids research 2013, 41(Database issue):D816-823.
29. Gene Ontology C: The Gene Ontology: enhancements for 2011. Nucleic acids research 2012, 40(Database issue):D559-564.
30. Bland JM, Altman DG: Multiple significance tests: the Bonferroni method. Bmj 1995, 310(6973):170.
31. Johansson R: System Modeling and Identification. 1993.
32. Pagano M, Gauvreau K: Principles of biostatistics. 2000.
33. Welcsh PL, Owens KN, King MC: Insights into the functions of BRCA1 and BRCA2. Trends Genet 2000, 16(2):69-74.
34. Komander D: The emerging complexity of protein ubiquitination. Biochemical Society transactions 2009, 37(Pt 5):937-953.
35. Hoeller D, Hecker CM, Dikic I: Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nature reviews Cancer 2006, 6(10):776-788.
36. Livinskaya VA, Ivanov VA, Fedorova OA, Vorontsova DN, Barlev NA, Nikiforov AA: Polyclonal antibodies against human proteasome subunits PSMA3, PSMA5, and PSMB5. Hybridoma 2012, 31(4):272-278.
37. Fedorova OA, Moiseeva TN, Nikiforov AA, Tsimokha AS, Livinskaya VA, Hodson M, Bottrill A, Evteeva IN, Ermolayeva JB, Kuznetzova IM et al: Proteomic analysis of the 20S proteasome (PSMA3)-interacting proteins reveals a functional link between the proteasome and mRNA metabolism. Biochemical and biophysical research communications 2011, 416(3-4):258-265.
38. Lodish H, Berk A, Kaiser C, Krieger M, Bretscher A, Ploegh H, Amon A, Scott M: Molecular Cell Biology 2013.
39. Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL: 2011: the immune hallmarks of cancer. Cancer immunology, immunotherapy : CII 2011, 60(3):319-326.
40. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100(1):57-70.
41. Nguyen VN, Mirejovsky P, Mirejovsky T, Melinova L, Mandys V: Expression of cyclin D1, Ki-67 and PCNA in non-small cell lung cancer: prognostic significance and comparison with p53 and bcl-2. Acta histochemica 2000, 102(3):323-338.
42. Saini S, Arora S, Majid S, Shahryari V, Chen Y, Deng G, Yamamura S, Ueno K, Dahiya R: Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer. Cancer prevention research 2011, 4(10):1698-1709.
43. Kihira S, Yoshida J, Kawada Y, Hitomi Y, Asada T, Hisatomi R, Ohta A, Iwasaki T, Mahbub Hasan AK, Fukami Y et al: Membrane microdomain-associated uroplakin IIIa contributes to Src-dependent mechanisms of anti-apoptotic proliferation in human bladder carcinoma cells. Biology open 2012, 1(10):1024-1034.
44. Lieu C, Kopetz S: The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy. Clinical colorectal cancer 2010, 9(2):89-94.
45. Ito Y, Kawakatsu H, Takeda T, Sakon M, Nagano H, Sakai T, Miyoshi E, Noda K, Tsujimoto M, Wakasa K et al: Activation of c-Src gene product in hepatocellular carcinoma is highly correlated with the indices of early stage phenotype. Journal of hepatology 2001, 35(1):68-73.
46. Byers LA, Sen B, Saigal B, Diao L, Wang J, Nanjundan M, Cascone T, Mills GB, Heymach JV, Johnson FM: Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2009, 15(22):6852-6861.
47. Lu B, Xu J, Zhu Y, Zhang H, Lai M: Systemic analysis of the differential gene expression profile in a colonic adenoma-normal SSH library. Clinica chimica acta; international journal of clinical chemistry 2007, 378(1-2):42-47.
48. Choi JE, Hur W, Jung CK, Piao LS, Lyoo K, Hong SW, Kim SW, Yoon HY, Yoon SK: Silencing of 14-3-3zeta over-expression in hepatocellular carcinoma inhibits tumor growth and enhances chemosensitivity to cis-diammined dichloridoplatium. Cancer letters 2011, 303(2):99-107.
49. Li Z, Zhao J, Du Y, Park HR, Sun SY, Bernal-Mizrachi L, Aitken A, Khuri FR, Fu H: Down-regulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(1):162-167.
50. Boorjian SA, Heemers HV, Frank I, Farmer SA, Schmidt LJ, Sebo TJ, Tindall DJ: Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocrine-related cancer 2009, 16(1):123-137.
51. Kim WJ, Lee JW, Quan C, Youn HJ, Kim HM, Bae SC: Nicotinamide inhibits growth of carcinogen induced mouse bladder tumor and human bladder tumor xenograft through up-regulation of RUNX3 and p300. The Journal of urology 2011, 185(6):2366-2375.
52. Ozawa A, Tanji N, Kikugawa T, Sasaki T, Yanagihara Y, Miura N, Yokoyama M: Inhibition of bladder tumour growth by histone deacetylase inhibitor. BJU international 2010, 105(8):1181-1186.
53. Niegisch G, Knievel J, Koch A, Hader C, Fischer U, Albers P, Schulz WA: Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. Urologic oncology 2012.
54. Xu XS, Wang L, Abrams J, Wang G: Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer. Journal of hematology & oncology 2011, 4:17.
55. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG: Roles of CREB-binding protein (CBP)/p300 in respiratory epithelium tumorigenesis. Cell research 2007, 17(4):324-332.
56. Weichert W: HDAC expression and clinical prognosis in human malignancies. Cancer letters 2009, 280(2):168-176.
57. Ishihama K, Yamakawa M, Semba S, Takeda H, Kawata S, Kimura S, Kimura W: Expression of HDAC1 and CBP/p300 in human colorectal carcinomas. Journal of clinical pathology 2007, 60(11):1205-1210.
58. Wilson AJ, Byun DS, Nasser S, Murray LB, Ayyanar K, Arango D, Figueroa M, Melnick A, Kao GD, Augenlicht LH et al: HDAC4 promotes growth of colon cancer cells via repression of p21. Molecular biology of the cell 2008, 19(10):4062-4075.
59. Mariadason JM: HDACs and HDAC inhibitors in colon cancer. Epigenetics : official journal of the DNA Methylation Society 2008, 3(1):28-37.
60. Dimova EY, Jakubowska MM, Kietzmann T: CREB binding to the hypoxia-inducible factor-1 responsive elements in the plasminogen activator inhibitor-1 promoter mediates the glucagon effect. Thrombosis and haemostasis 2007, 98(2):296-303.
61. Li M, Luo RZ, Chen JW, Cao Y, Lu JB, He JH, Wu QL, Cai MY: High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma. Journal of translational medicine 2011, 9:5.
62. Quint K, Agaimy A, Di Fazio P, Montalbano R, Steindorf C, Jung R, Hellerbrand C, Hartmann A, Sitter H, Neureiter D et al: Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Archiv : an international journal of pathology 2011, 459(2):129-139.
63. Xie HJ, Noh JH, Kim JK, Jung KH, Eun JW, Bae HJ, Kim MG, Chang YG, Lee JY, Park H et al: HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer. PloS one 2012, 7(4):e34265.
64. Zhang J, Yang Y, Yang T, Liu Y, Li A, Fu S, Wu M, Pan Z, Zhou W: microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. British journal of cancer 2010, 103(8):1215-1220.
65. Hou X, Li Y, Luo RZ, Fu JH, He JH, Zhang LJ, Yang HX: High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2012, 38(6):523-530.
66. Kishimoto M, Kohno T, Okudela K, Otsuka A, Sasaki H, Tanabe C, Sakiyama T, Hirama C, Kitabayashi I, Minna JD et al: Mutations and deletions of the CBP gene in human lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2005, 11(2 Pt 1):512-519.
67. Jung KH, Noh JH, Kim JK, Eun JW, Bae HJ, Xie HJ, Chang YG, Kim MG, Park H, Lee JY et al: HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins. Journal of cellular biochemistry 2012, 113(6):2167-2177.
68. Sasaki H, Moriyama S, Nakashima Y, Kobayashi Y, Kiriyama M, Fukai I, Yamakawa Y, Fujii Y: Histone deacetylase 1 mRNA expression in lung cancer. Lung cancer 2004, 46(2):171-178.
69. Osada H, Tatematsu Y, Sugito N, Horio Y, Takahashi T: Histone modification in the TGFbetaRII gene promoter and its significance for responsiveness to HDAC inhibitor in lung cancer cell lines. Molecular carcinogenesis 2005, 44(4):233-241.
70. Bi G, Jiang G: The molecular mechanism of HDAC inhibitors in anticancer effects. Cellular & molecular immunology 2006, 3(4):285-290.
71. Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI, Peltola M, Smit F, Verhaegh G, Schalken J et al: TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer research 2006, 66(21):10242-10246.
72. Hirata H, Hinoda Y, Ueno K, Shahryari V, Tabatabai ZL, Dahiya R: MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer. Carcinogenesis 2012, 33(1):41-48.
73. Barker N, Clevers H: Mining the Wnt pathway for cancer therapeutics. Nature reviews Drug discovery 2006, 5(12):997-1014.
74. Maier TJ, Janssen A, Schmidt R, Geisslinger G, Grosch S: Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2005, 19(10):1353-1355.
75. Fatima S, Lee NP, Luk JM: Dickkopfs and Wnt/beta-catenin signalling in liver cancer. World journal of clinical oncology 2011, 2(8):311-325.
76. Ozen C, Yildiz G, Dagcan A, Cevik D, Ors A, Keles U, Topel H, Ozturk M: Genetics and epigenetics of liver cancer. New biotechnology 2013.
77. Sun L, Fu BB, Liu DG: Systemic delivery of full-length C/EBP beta/liposome complex suppresses growth of human colon cancer in nude mice. Cell research 2005, 15(10):770-776.
78. Flodby P, Liao DZ, Blanck A, Xanthopoulos KG, Hallstrom IP: Expression of the liver-enriched transcription factors C/EBP alpha, C/EBP beta, HNF-1, and HNF-4 in preneoplastic nodules and hepatocellular carcinoma in rat liver. Molecular carcinogenesis 1995, 12(2):103-109.
79. Xi S, Yang M, Tao Y, Xu H, Shan J, Inchauste S, Zhang M, Mercedes L, Hong JA, Rao M et al: Cigarette smoke induces C/EBP-beta-mediated activation of miR-31 in normal human respiratory epithelia and lung cancer cells. PloS one 2010, 5(10):e13764.
80. Ikezoe T, Yang Y, Saitoh T, Heber D, McKenna R, Taguchi H, Koeffler HP: PC-SPES down-regulates COX-2 via inhibition of NF-kappaB and C/EBPbeta in non-small cell lung cancer cells. International journal of oncology 2006, 29(2):453-461.
81. Teng J, Wang ZY, Jarrard DF, Bjorling DE: Roles of estrogen receptor alpha and beta in modulating urothelial cell proliferation. Endocrine-related cancer 2008, 15(1):351-364.
82. Nussler NC, Reinbacher K, Shanny N, Schirmeier A, Glanemann M, Neuhaus P, Nussler AK, Kirschner M: Sex-specific differences in the expression levels of estrogen receptor subtypes in colorectal cancer. Gender medicine 2008, 5(3):209-217.
83. Shen R, Tao L, Xu Y, Chang S, Van Brocklyn J, Gao JX: Reversibility of aberrant global DNA and estrogen receptor-alpha gene methylation distinguishes colorectal precancer from cancer. International journal of clinical and experimental pathology 2009, 2(1):21-33.
84. Freise C, Ruehl M, Seehofer D, Hoyer J, Somasundaram R: The inhibitor of Ca(2+)-dependent K (+) channels TRAM-34 blocks growth of hepatocellular carcinoma cells via downregulation of estrogen receptor alpha mRNA and nuclear factor-kappaB. Investigational new drugs 2013, 31(2):452-457.
85. Liu WH, Yeh SH, Lu CC, Yu SL, Chen HY, Lin CY, Chen DS, Chen PJ: MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology 2009, 136(2):683-693.
86. Henderson BE, Feigelson HS: Hormonal carcinogenesis. Carcinogenesis 2000, 21(3):427-433.
87. Schmitz-Drager BJ, Schulz WA, Jurgens B, Gerharz CD, van Roeyen CR, Bultel H, Ebert T, Ackermann R: c-myc in bladder cancer. Clinical findings and analysis of mechanism. Urological research 1997, 25 Suppl 1:S45-49.
88. Watters AD, Latif Z, Forsyth A, Dunn I, Underwood MA, Grigor KM, Bartlett JM: Genetic aberrations of c-myc and CCND1 in the development of invasive bladder cancer. British journal of cancer 2002, 87(6):654-658.
89. Tang Y, Simoneau AR, Liao WX, Yi G, Hope C, Liu F, Li S, Xie J, Holcombe RF, Jurnak FA et al: WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells. Molecular cancer therapeutics 2009, 8(2):458-468.
90. Smith DR, Myint T, Goh HS: Over-expression of the c-myc proto-oncogene in colorectal carcinoma. British journal of cancer 1993, 68(2):407-413.
91. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD et al: MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004, 431(7012):1112-1117.
92. Zajac-Kaye M: Myc oncogene: a key component in cell cycle regulation and its implication for lung cancer. Lung cancer 2001, 34 Suppl 2:S43-46.
93. Kawana H, Tamaru J, Tanaka T, Hirai A, Saito Y, Kitagawa M, Mikata A, Harigaya K, Kuriyama T: Role of p27Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer. The American journal of pathology 1998, 153(2):505-513.
94. Yamamoto H, Monden T, Ikeda K, Izawa H, Fukuda K, Fukunaga M, Tomita N, Shimano T, Shiozaki H, Monden M: Coexpression of cdk2/cdc2 and retinoblastoma gene products in colorectal cancer. British journal of cancer 1995, 71(6):1231-1236.
95. Li KK, Ng IO, Fan ST, Albrecht JH, Yamashita K, Poon RY: Activation of cyclin-dependent kinases CDC2 and CDK2 in hepatocellular carcinoma. Liver 2002, 22(3):259-268.
96. Huang WW, Yang JS, Pai SJ, Wu PP, Chang SJ, Chueh FS, Fan MJ, Chiou SM, Kuo HM, Yeh CC et al: Bufalin induces G(0)/G(1) phase arrest through inhibiting the levels of cyclin D, cyclin E, CDK2 and CDK4, and triggers apoptosis via mitochondrial signaling pathway in T24 human bladder cancer cells. Mutation research 2012, 732(1-2):26-33.
97. Aleem E, Berthet C, Kaldis P: Cdk2 as a Master of S phase Entry: Fact or Fake? Cell cycle 2004(3):35–37.
98. Lianes P, Orlow I, Zhang ZF, Oliva MR, Sarkis AS, Reuter VE, Cordon-Cardo C: Altered patterns of MDM2 and TP53 expression in human bladder cancer. Journal of the National Cancer Institute 1994, 86(17):1325-1330.
99. Simon R, Struckmann K, Schraml P, Wagner U, Forster T, Moch H, Fijan A, Bruderer J, Wilber K, Mihatsch MJ et al: Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene 2002, 21(16):2476-2483.
100. Ray RM, Bhattacharya S, Johnson LR: Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1. Apoptosis : an international journal on programmed cell death 2011, 16(1):35-44.
101. Endo K, Ueda T, Ohta T, Terada T: Protein expression of MDM2 and its clinicopathological relationships in human hepatocellular carcinoma. Liver 2000, 20(3):209-215.
102. Higashiyama M, Doi O, Kodama K, Yokouchi H, Kasugai T, Ishiguro S, Takami K, Nakayama T, Nishisho I: MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. British journal of cancer 1997, 75(9):1302-1308.
103. Asahara H, Li Y, Fuss J, Haines DS, Vlatkovic N, Boyd MT, Linn S: Stimulation of human DNA polymerase epsilon by MDM2. Nucleic acids research 2003, 31(9):2451-2459.
104. Vlatkovic N, Guerrera S, Li Y, Linn S, Haines DS, Boyd MT: MDM2 interacts with the C-terminus of the catalytic subunit of DNA polymerase epsilon. Nucleic acids research 2000, 28(18):3581-3586.
105. Lee J, Zhou P: Cullins and cancer. Genes & cancer 2010, 1(7):690-699.
106. Salon C, Brambilla E, Brambilla C, Lantuejoul S, Gazzeri S, Eymin B: Altered pattern of Cul-1 protein expression and neddylation in human lung tumours: relationships with CAND1 and cyclin E protein levels. The Journal of pathology 2007, 213(3):303-310.
107. Grau L, Luque-Garcia JL, Gonzalez-Peramato P, Theodorescu D, Palou J, Fernandez-Gomez JM, Sanchez-Carbayo M: A quantitative proteomic analysis uncovers the relevance of CUL3 in bladder cancer aggressiveness. PloS one 2013, 8(1):e53328.
108. Lee DF, Kuo HP, Liu M, Chou CK, Xia W, Du Y, Shen J, Chen CT, Huo L, Hsu MC et al: KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta. Molecular cell 2009, 36(1):131-140.
109. Du M, Sansores-Garcia L, Zu Z, Wu KK: Cloning and expression analysis of a novel salicylate suppressible gene, Hs-CUL-3, a member of cullin/Cdc53 family. The Journal of biological chemistry 1998, 273(38):24289-24292.
110. Kossatz U, Breuhahn K, Wolf B, Hardtke-Wolenski M, Wilkens L, Steinemann D, Singer S, Brass F, Kubicka S, Schlegelberger B et al: The cyclin E regulator cullin 3 prevents mouse hepatic progenitor cells from becoming tumor-initiating cells. The Journal of clinical investigation 2010, 120(11):3820-3833.
111. Thu KL, Pikor LA, Chari R, Wilson IM, Macaulay CE, English JC, Tsao MS, Gazdar AF, Lam S, Lam WL et al: Genetic disruption of KEAP1/CUL3 E3 ubiquitin ligase complex components is a key mechanism of NF-kappaB pathway activation in lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011, 6(9):1521-1529.
112. Inagaki T, Ebisuno S, Uekado Y, Hirano A, Hiroi A, Shinka T, Ohkawa T: PCNA and p53 in urinary bladder cancer: correlation with histological findings and prognosis. International journal of urology : official journal of the Japanese Urological Association 1997, 4(2):172-177.
113. McKay JA, Douglas JJ, Ross VG, Curran S, Loane JF, Ahmed FY, Cassidy J, McLeod HL, Murray GI: Analysis of key cell-cycle checkpoint proteins in colorectal tumours. The Journal of pathology 2002, 196(4):386-393.
114. Qasim BJ, Ali HH, Hussein AG: Immunohistochemical expression of PCNA and CD34 in colorectal adenomas and carcinomas using specified automated cellular image analysis system: a clinicopathologic study. Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association 2012, 18(4):268-276.
115. Stroescu C, Dragnea A, Ivanov B, Pechianu C, Herlea V, Sgarbura O, Popescu A, Popescu I: Expression of p53, Bcl-2, VEGF, Ki67 and PCNA and prognostic significance in hepatocellular carcinoma. Journal of gastrointestinal and liver diseases : JGLD 2008, 17(4):411-417.
116. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
117. Ali MJ, Parsam VL, Honavar SG, Kannabiran C, Vemuganti GK, Reddy VAP: RB1 gene mutations in retinoblastoma and its clinical correlation. Saudi Journal of Ophthalmology 2010, 24(4):119-123.
118. Muller PA, Vousden KH: p53 mutations in cancer. Nature cell biology 2013, 15(1):2-8.
119. Chatterjee SJ, George B, Goebell PJ, Alavi-Tafreshi M, Shi SR, Fung YK, Jones PA, Cordon-Cardo C, Datar RH, Cote RJ: Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer. The Journal of pathology 2004, 203(3):762-770.
120. Llovet JM, Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48(4):1312-1327.
121. Azechi H, Nishida N, Fukuda Y, Nishimura T, Minata M, Katsuma H, Kuno M, Ito T, Komeda T, Kita R et al: Disruption of the p16/cyclin D1/retinoblastoma protein pathway in the majority of human hepatocellular carcinomas. Oncology 2001, 60(4):346-354.
122. Tanaka H, Fujii Y, Hirabayashi H, Miyoshi S, Sakaguchi M, Yoon HE, Matsuda H: Disruption of the RB pathway and cell-proliferative activity in non-small-cell lung cancers. International journal of cancer Journal international du cancer 1998, 79(2):111-115.
123. Kitamura H, Yazawa T, Sato H, Okudela K, Shimoyamada H: Small cell lung cancer: significance of RB alterations and TTF-1 expression in its carcinogenesis, phenotype, and biology. Endocrine pathology 2009, 20(2):101-107.
124. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991, 253(5015):49-53.
125. Iacopetta B: TP53 mutation in colorectal cancer. Human mutation 2003, 21(3):271-276.
126. Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM: Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clinical cancer research : an official journal of the American Association for Cancer Research 2005, 11(11):3974-3986.
127. Hsu FM, Zhang S, Chen BP: Role of DNA-dependent protein kinase catalytic subunit in cancer development and treatment. Translational cancer research 2012, 1(1):22-34.
128. Wang SY, Peng L, Li CP, Li AP, Zhou JW, Zhang ZD, Liu QZ: Genetic variants of the XRCC7 gene involved in DNA repair and risk of human bladder cancer. International journal of urology : official journal of the Japanese Urological Association 2008, 15(6):534-539.
129. Hosoi Y, Watanabe T, Nakagawa K, Matsumoto Y, Enomoto A, Morita A, Nagawa H, Suzuki N: Up-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal cancer. International journal of oncology 2004, 25(2):461-468.
130. Lu Y, Zhang HL, Li YZ, Zhao P: [Clinicopathological significance of expressions of DNA dependent protein kinase catalytic subunit and P16 in colorectal carcinoma]. Zhonghua yi xue za zhi 2008, 88(29):2025-2029.
131. Long XD, Yao JG, Huang YZ, Huang XY, Ban FZ, Yao LM, Fan LD: DNA repair gene XRCC7 polymorphisms (rs#7003908 and rs#10109984) and hepatocellular carcinoma related to AFB1 exposure among Guangxi population, China. Hepatology research : the official journal of the Japan Society of Hepatology 2011, 41(11):1085-1093.
132. Xing J, Wu X, Vaporciyan AA, Spitz MR, Gu J: Prognostic significance of ataxia-telangiectasia mutated, DNA-dependent protein kinase catalytic subunit, and Ku heterodimeric regulatory complex 86-kD subunit expression in patients with nonsmall cell lung cancer. Cancer 2008, 112(12):2756-2764.
133. Hao Y, Hu X, Liu Y, Jin B, Wen H, Hou K, Kang J: [The expression of ERCC1, DNA-PKcs protein and the relation to prognosis in non-small cell lung cancer.]. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2008, 11(2):226-230.
134. Walker JR, Corpina RA, Goldberg J: Structure of the Ku heterodimer bound to DNA and its implications for double-strand break repair. Nature 2001, 412(6847):607-614.
135. Pucci S, Mazzarelli P, Rabitti C, Giai M, Gallucci M, Flammia G, Alcini A, Altomare V, Fazio VM: Tumor specific modulation of KU70/80 DNA binding activity in breast and bladder human tumor biopsies. Oncogene 2001, 20(6):739-747.
136. Mazzarelli P, Parrella P, Seripa D, Signori E, Perrone G, Rabitti C, Borzomati D, Gabbrielli A, Matera MG, Gravina C et al: DNA end binding activity and Ku70/80 heterodimer expression in human colorectal tumor. World journal of gastroenterology : WJG 2005, 11(42):6694-6700.
137. Hsu CM, Yang MD, Chang WS, Jeng LB, Lee MH, Lu MC, Chang SC, Tsai CW, Tsai Y, Tsai FJ et al: The Contribution of XRCC6/Ku70 to Hepatocellular Carcinoma in Taiwan. Anticancer research 2013, 33(2):529-535.
138. Busser B, Sancey L, Josserand V, Niang C, Khochbin S, Favrot MC, Coll JL, Hurbin A: Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation. Molecular therapy : the journal of the American Society of Gene Therapy 2010, 18(3):536-543.
139. Bau DT, Tsai CW, Wu CN: Role of the XRCC5/XRCC6 dimer in carcinogenesis and pharmacogenomics. Pharmacogenomics 2011, 12(4):515-534.
140. Suchy J, Cybulski C, Gorski B, Huzarski T, Byrski T, Debniak T, Gronwald J, Jakubowska A, Wokolorczyk D, Kurzawski G et al: BRCA1 mutations and colorectal cancer in Poland. Familial cancer 2010, 9(4):541-544.
141. Grabsch H, Dattani M, Barker L, Maughan N, Maude K, Hansen O, Gabbert HE, Quirke P, Mueller W: Expression of DNA double-strand break repair proteins ATM and BRCA1 predicts survival in colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2006, 12(5):1494-1500.
142. Gachechiladze M, Skarda J: The role of BRCA1 in non-small cell lung cancer. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 2012, 156(3):200-203.
143. Simpson F, Lammerts van Bueren K, Butterfield N, Bennetts JS, Bowles J, Adolphe C, Simms LA, Young J, Walsh MD, Leggett B et al: The PCNA-associated factor KIAA0101/p15(PAF) binds the potential tumor suppressor product p33ING1b. Experimental cell research 2006, 312(1):73-85.
144. Liu L, Chen X, Xie S, Zhang C, Qiu Z, Zhu F: Variant 1 of KIAA0101, overexpressed in hepatocellular carcinoma, prevents doxorubicin-induced apoptosis by inhibiting p53 activation. Hepatology 2012, 56(5):1760-1769.
145. Kato T, Daigo Y, Aragaki M, Ishikawa K, Sato M, Kaji M: Overexpression of KIAA0101 predicts poor prognosis in primary lung cancer patients. Lung cancer 2012, 75(1):110-118.
146. Iwano T, Tachibana M, Reth M, Shinkai Y: Importance of TRF1 for functional telomere structure. The Journal of biological chemistry 2004, 279(2):1442-1448.
147. Hu H, Zhang Y, Zou M, Yang S, Liang XQ: Expression of TRF1, TRF2, TIN2, TERT, KU70, and BRCA1 proteins is associated with telomere shortening and may contribute to multistage carcinogenesis of gastric cancer. Journal of cancer research and clinical oncology 2010, 136(9):1407-1414.
148. Garcia-Aranda C, de Juan C, Diaz-Lopez A, Sanchez-Pernaute A, Torres AJ, Diaz-Rubio E, Balibrea JL, Benito M, Iniesta P: Correlations of telomere length, telomerase activity, and telomeric-repeat binding factor 1 expression in colorectal carcinoma. Cancer 2006, 106(3):541-551.
149. Igarashi M, Suda T, Hara H, Takimoto M, Nomoto M, Takahashi T, Okoshi S, Kawai H, Mita Y, Waguri N et al: Interferon can block telomere erosion and in rare cases result in hepatocellular carcinoma development with telomeric repeat binding factor 1 overexpression in chronic hepatitis C. Clinical cancer research : an official journal of the American Association for Cancer Research 2003, 9(14):5264-5270.
150. Hu J, Sun L, Zhang C, Zhou X: Expression of telomeric repeat binding factor 1 in non-small cell lung cancer. Journal of surgical oncology 2006, 93(1):62-67.
151. Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 2010, 140(6):883-899.
152. Zheng QY, Li PP, Jin FS, Yao C, Zhang GH, Zang T, Ai X: Ursolic acid induces ER stress response to activate ASK1-JNK signaling and induce apoptosis in human bladder cancer T24 cells. Cellular signalling 2013, 25(1):206-213.
153. Dai S, Jiang L, Wang G, Zhou X, Wei X, Cheng H, Wu Z, Wei D: HSP70 interacts with TRAF2 and differentially regulates TNFalpha signalling in human colon cancer cells. Journal of cellular and molecular medicine 2010, 14(3):710-725.
154. Luedde T, Schwabe RF: NF-kappaB in the liver--linking injury, fibrosis and hepatocellular carcinoma. Nature reviews Gastroenterology & hepatology 2011, 8(2):108-118.
155. Zheng M, Morgan-Lappe SE, Yang J, Bockbrader KM, Pamarthy D, Thomas D, Fesik SW, Sun Y: Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2. Cancer research 2008, 68(18):7570-7578.
156. Andersen JB, Aaboe M, Borden EC, Goloubeva OG, Hassel BA, Orntoft TF: Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. British journal of cancer 2006, 94(10):1465-1471.
157. Wood LM, Pan ZK, Seavey MM, Muthukumaran G, Paterson Y: The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy. Cancer immunology, immunotherapy : CII 2012, 61(5):689-700.
158. Desai SD, Haas AL, Wood LM, Tsai YC, Pestka S, Rubin EH, Saleem A, Nur EKA, Liu LF: Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway. Cancer research 2006, 66(2):921-928.
159. Breuhahn K, Vreden S, Haddad R, Beckebaum S, Stippel D, Flemming P, Nussbaum T, Caselmann WH, Haab BB, Schirmacher P: Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. Cancer research 2004, 64(17):6058-6064.
160. Feng Q, Sekula D, Guo Y, Liu X, Black CC, Galimberti F, Shah SJ, Sempere LF, Memoli V, Andersen JB et al: UBE1L causes lung cancer growth suppression by targeting cyclin D1. Molecular cancer therapeutics 2008, 7(12):3780-3788.
161. Bektas N, Noetzel E, Veeck J, Press MF, Kristiansen G, Naami A, Hartmann A, Dimmler A, Beckmann MW, Knuchel R et al: The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer. Breast cancer research : BCR 2008, 10(4):R58.
162. Liu G, Park YJ, Abraham E: Interleukin-1 receptor-associated kinase (IRAK) -1-mediated NF-kappaB activation requires cytosolic and nuclear activity. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2008, 22(7):2285-2296.
163. Behrens C, Feng L, Kadara H, Kim HJ, Lee JJ, Mehran R, Hong WK, Lotan R, Wistuba, II: Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesions. Clinical cancer research : an official journal of the American Association for Cancer Research 2010, 16(1):34-44.
164. Kogo R, Mimori K, Tanaka F, Komune S, Mori M: Clinical significance of miR-146a in gastric cancer cases. Clinical cancer research : an official journal of the American Association for Cancer Research 2011, 17(13):4277-4284.
165. Sun J, Wiklund F, Hsu FC, Balter K, Zheng SL, Johansson JE, Chang B, Liu W, Li T, Turner AR et al: Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2006, 15(3):480-485.
166. Satoh J: Molecular network of microRNA targets in Alzheimer's disease brains. Experimental neurology 2012, 235(2):436-446.
167. Kanehisa M: Molecular network analysis of diseases and drugs in KEGG. Methods in molecular biology 2013, 939:263-275.
168. Huang da W, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature protocols 2009, 4(1):44-57.
169. Williams GH, Stoeber K: The cell cycle and cancer. The Journal of pathology 2012, 226(2):352-364.
170. Polakis P: Wnt signaling in cancer. Cold Spring Harbor perspectives in biology 2012, 4(5).
171. Allenspach EJ, Maillard I, Aster JC, Pear WS: Notch signaling in cancer. Cancer biology & therapy 2002, 1(5):466-476.
172. Bolos V, Grego-Bessa J, de la Pompa JL: Notch signaling in development and cancer. Endocrine reviews 2007, 28(3):339-363.
173. Schneikert J, Behrens J: The canonical Wnt signalling pathway and its APC partner in colon cancer development. Gut 2007, 56(3):417-425.
174. Derynck R, Akhurst RJ, Balmain A: TGF-beta signaling in tumor suppression and cancer progression. Nature genetics 2001, 29(2):117-129.
175. Xiong Y, Jia X: [Reasearch advances on lung cancer stem cell]. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2010, 13(3):260-264.
176. Kawai T, Akira S: Toll-like receptor and RIG-I-like receptor signaling. Annals of the New York Academy of Sciences 2008, 1143:1-20.
177. Bioseeker: RIG-I-like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2013. April 2013.
178. Markowitz SD, Bertagnolli MM: Molecular origins of cancer: Molecular basis of colorectal cancer. The New England journal of medicine 2009, 361(25):2449-2460.
179. Taniue K, Oda T, Hayashi T, Okuno M, Akiyama T: A member of the ETS family, EHF, and the ATPase RUVBL1 inhibit p53-mediated apoptosis. EMBO reports 2011, 12(7):682-689.
180. Hwang J, Winkler L, Kalejta RF: Ubiquitin-independent proteasomal degradation during oncogenic viral infections. Biochimica et biophysica acta 2011, 1816(2):147-157.
181. Bardag-Gorce F: Proteasome inhibitor treatment in alcoholic liver disease. World journal of gastroenterology : WJG 2011, 17(20):2558-2562.
182. Levine L: Proteasome inhibitors: their effects on arachidonic acid release from cells in culture and arachidonic acid metabolism in rat liver cells. BMC pharmacology 2004, 4:15.
183. Dai P, Liu X, Li QW: [Function of the Lck and Fyn in T cell development]. Yi chuan = Hereditas / Zhongguo yi chuan xue hui bian ji 2012, 34(3):289-295.
184. Pedroza-Gonzalez A, Verhoef C, Ijzermans JN, Peppelenbosch MP, Kwekkeboom J, Verheij J, Janssen HL, Sprengers D: Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology 2013, 57(1):183-194.
185. Cronin SJ, Penninger JM: From T-cell activation signals to signaling control of anti-cancer immunity. Immunological reviews 2007, 220:151-168.
186. Helleday T: Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis 2010, 31(6):955-960.
187. Saviozzi S, Ceppi P, Novello S, Ghio P, Lo Iacono M, Borasio P, Cambieri A, Volante M, Papotti M, Calogero RA et al: Non-small cell lung cancer exhibits transcript overexpression of genes associated with homologous recombination and DNA replication pathways. Cancer research 2009, 69(8):3390-3396.
188. Sanchez-Palencia A, Gomez-Morales M, Gomez-Capilla JA, Pedraza V, Boyero L, Rosell R, Farez-Vidal ME: Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancer. International journal of cancer Journal international du cancer 2011, 129(2):355-364.
189. Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, Dasgupta A, Mann FE, Fukuoka J, Hames M, Bergen AW et al: Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PloS one 2008, 3(2):e1651.
190. Tun HW, Marlow LA, von Roemeling CA, Cooper SJ, Kreinest P, Wu K, Luxon BA, Sinha M, Anastasiadis PZ, Copland JA: Pathway signature and cellular differentiation in clear cell renal cell carcinoma. PloS one 2010, 5(5):e10696.
191. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, Stephens RM, Caporaso NE, Loffredo CA, Ambs S: Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer research 2008, 68(3):927-936.
192. Cancer Genome Atlas Research N: Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. The New England journal of medicine 2013, 368(22):2059-2074.
193. Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R et al: Integrated genomic characterization of endometrial carcinoma. Nature 2013, 497(7447):67-73.
194. Guo H, Zhu YP, Li D, He FC: [Identification, modeling and simulation of key pathways underlying certain cancers]. Yi chuan = Hereditas / Zhongguo yi chuan xue hui bian ji 2011, 33(8):809-819.
195. Wu D, Rice CM, Wang X: Cancer bioinformatics: a new approach to systems clinical medicine. BMC bioinformatics 2012, 13:71.
196. Rivlin N, Brosh R, Oren M, Rotter V: Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes & cancer 2011, 2(4):466-474.
197. Danes CG, Wyszomierski SL, Lu J, Neal CL, Yang W, Yu D: 14-3-3 zeta down-regulates p53 in mammary epithelial cells and confers luminal filling. Cancer research 2008, 68(6):1760-1767.
198. Wang W, Liu Z, Qu P, Zhou Z, Zeng Y, Fan J, Liu Y, Guo Y, Qiu J: Knockdown of regulator of cullins-1 (ROC1) expression induces bladder cancer cell cycle arrest at the G2 phase and senescence. PloS one 2013, 8(5):e62734.
199. Korzeniewski N, Zheng L, Cuevas R, Parry J, Chatterjee P, Anderton B, Duensing A, Munger K, Duensing S: Cullin 1 functions as a centrosomal suppressor of centriole multiplication by regulating polo-like kinase 4 protein levels. Cancer research 2009, 69(16):6668-6675.
200. Peng Z, Wang H, Shan C: Expression of ubiquitin and cullin-1 and its clinicopathological significance in benign and malignant lesions of the lung. Zhong nan da xue xue bao Yi xue ban = Journal of Central South University Medical sciences 2009, 34(3):204-209.
201. Yu H, Zou Y, Jiang L, Yin Q, He X, Chen L, Zhang Z, Gu W, Li Y: Induction of apoptosis in non-small cell lung cancer by downregulation of MDM2 using pH-responsive PMPC-b-PDPA/siRNA complex nanoparticles. Biomaterials 2013, 34(11):2738-2747.
202. Tu CT, Chen BS: New measurement methods of network robustness and response ability via microarray data. PloS one 2013, 8(1):e55230.
|